Results 81 to 90 of about 2,113,172 (249)
Quarterly; Vol. 1, issue 1 (spring 2002)-; Title from PDF caption (publisher's web site, viewed Mar. 5, 2007).; Latest issue consulted: Vol.
core
Sex Representation in US Stroke Clinical Trials: A Decade of Trends and Challenges
ABSTRACT Objective Stroke remains a major cause of disability and mortality in the US, with significant sex‐based disparities, and females remain underrepresented in stroke clinical trials. We aimed to examine sex representation in US‐based stroke clinical trials, identify trial characteristics associated with higher female enrollment (≥ 50%), and ...
Chaitali Dagli +5 more
wiley +1 more source
Quarterly; Vol. 1, issue 1 (spring 2002)-; Title from PDF caption (publisher's web site, viewed Mar. 5, 2007).; Latest issue consulted: Vol.
core
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Gyermekkorban végzett CT vizsgálatok protokoll-optimalizálási lehetőségei
A gyerekkorban végzett CT vizsgálatok száma növekvő tendenciát mutat napjainkban, ezért fontos, hogy a vizsgálati protokollok megfelelően legyenek kidolgozva, optimalizálva és alkalmazva a lehetséges kockázat minimalizálásáért.
Csuka, Viktória
core
Quarterly; Vol. 1, issue 1 (spring 2002)-; Title from PDF caption (publisher's web site, viewed Mar. 5, 2007).; Latest issue consulted: Vol.
core
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Quarterly; Vol. 1, issue 1 (spring 2002)-; Title from PDF caption (publisher's web site, viewed Mar. 5, 2007).; Latest issue consulted: Vol.
core
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Quarterly; Vol. 1, issue 1 (spring 2002)-; Title from PDF caption (publisher's web site, viewed Mar. 5, 2007).; Latest issue consulted: Vol.
core

